摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloromethyl-3,5,7,8-tetrahydro-pyrano[4,3-d]pyrimidin-4-one | 1417917-59-9

中文名称
——
中文别名
——
英文名称
2-chloromethyl-3,5,7,8-tetrahydro-pyrano[4,3-d]pyrimidin-4-one
英文别名
2-(Chloromethyl)-7,8-dihydro-3H-pyrano[4,3-D]pyrimidin-4(5H)-one;2-(chloromethyl)-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one
2-chloromethyl-3,5,7,8-tetrahydro-pyrano[4,3-d]pyrimidin-4-one化学式
CAS
1417917-59-9
化学式
C8H9ClN2O2
mdl
——
分子量
200.625
InChiKey
RPZAUKYBUXOJNX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    350.3±52.0 °C(Predicted)
  • 密度:
    1.58±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    50.7
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    2-chloromethyl-3,5,7,8-tetrahydro-pyrano[4,3-d]pyrimidin-4-one 在 sodium azide 作用下, 以 丙酮 为溶剂, 反应 36.0h, 以19.25 g的产率得到2-(azidomethyl)-7,8-dihydro-3H-pyrano[4,3-d]pyrimidin-4(5H)-one
    参考文献:
    名称:
    [EN] NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS
    [FR] NOUVEAUX COMPOSÉS 2-PIPERIDIN-1-YL-ACETAMIDE UTILISABLES EN TANT QU'INHIBITEURS DE TANKYRASE
    摘要:
    本发明提供了式(I)的化合物,其中R1-R5和L在此处定义。本发明还提供了包含式(I)化合物的药物组合物和组合物,以及将这些化合物用作坦基酶抑制剂以及用于治疗Wnt信号和坦基酶1和2信号相关疾病的用途,包括但不限于癌症。
    公开号:
    WO2013012723A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    [EN] NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS
    [FR] NOUVEAUX COMPOSÉS 2-PIPERIDIN-1-YL-ACETAMIDE UTILISABLES EN TANT QU'INHIBITEURS DE TANKYRASE
    摘要:
    本发明提供了式(I)的化合物,其中R1-R5和L在此处定义。本发明还提供了包含式(I)化合物的药物组合物和组合物,以及将这些化合物用作坦基酶抑制剂以及用于治疗Wnt信号和坦基酶1和2信号相关疾病的用途,包括但不限于癌症。
    公开号:
    WO2013012723A1
点击查看最新优质反应信息

文献信息

  • [EN] 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS<br/>[FR] COMPOSÉS DE 4-PIPÉRIDINYLE UTILES COMME INHIBITEURS DE LA TANKYRASE
    申请人:NOVARTIS AG
    公开号:WO2013008217A1
    公开(公告)日:2013-01-17
    The present invention provides for compounds of formula (I).The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.
    本发明提供了化合物的结构式(I)。本发明还提供了包含结构式(I)化合物的药物组合物和组合物,以及利用这些化合物作为坦基酶抑制剂,并用于治疗Wnt信号和与坦基酶1和2信号相关的疾病,包括但不限于癌症。
  • [EN] 4-OXO-3,5,7,8-TETRAHYDRO-4H-PYRANO {4,3-D} PYRMINIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS<br/>[FR] COMPOSÉS DE 4-OXO-3,5,7,8-TÉTRAHYDRO-4H-PYRANO{4,3-D}PYRIMINIDINYLE UTILISABLES À TITRE D'INHIBITEURS DE TANKYRASES
    申请人:NOVARTIS AG
    公开号:WO2013010092A1
    公开(公告)日:2013-01-17
    The present invention provides for compounds of formula (I) wherein R1 and R2 are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.
    本发明提供了以下式(I)中R1和R2被定义的化合物。本发明还提供了含有式(I)化合物的药物组合物和配方,以及将这些化合物用作坦基酶抑制剂以及用于治疗Wnt信号和坦基酶1和2信号相关疾病的用途,包括但不限于癌症。
  • 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS
    申请人:Chen Christine Hiu-Tung
    公开号:US20150126513A1
    公开(公告)日:2015-05-07
    The present invention provides for compounds of formula (I): wherein R 1 -R 4 and n are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.
    本发明提供了公式(I)的化合物:其中R1-R4和n在此定义。本发明还提供了包括公式(I)化合物的制药组合物和组合物,以及将这些化合物用作坦克酰酶抑制剂,并用于治疗与Wnt信号和坦克酰酶1和2信号相关的疾病,包括但不限于癌症。
  • NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS
    申请人:Cheung Atwood Kim
    公开号:US20150025070A1
    公开(公告)日:2015-01-22
    The present invention provides for compounds of formula (I): wherein R 1 -R 5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.
    本发明提供了公式(I)的化合物:其中R1-R5和L在此定义。本发明还提供了含有公式(I)化合物的药物组合物和组合物,以及将这些化合物用作坦克酶抑制剂和治疗与Wnt信号和坦克酶1和2信号相关的疾病的用途,包括但不限于癌症。
  • 4-piperidinyl compounds for use as tankyrase inhibitors
    申请人:Chen Christine Hiu-Tung
    公开号:US09163003B2
    公开(公告)日:2015-10-20
    The present invention provides for compounds of formula (I): wherein R1-R4 and n are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.
    本发明提供了式(I)的化合物:其中R1-R4和n在此定义。本发明还提供了包含式(I)化合物的药物组合物和组合物,以及将这些化合物用作坦克酶抑制剂和治疗与Wnt信号和坦克酶1和2信号相关的疾病的用途,包括但不限于癌症。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione